Barts Health adopts AI for high risk colon cancer patients

Share:

Share on twitter
Share on linkedin
Share on facebook
Share on email

Barts Health adopts AI for high risk colon cancer patients

Barts Health NHS Trust has implemented an artificial intelligence platform to help identify and prioritise patients at high risk of developing colon cancer.

The tool from Medial EarlySign is being used to identify patients most likely to benefit from further evaluation and intervention. The company said the algorithms help to identify patients by analysing existing routine clinical data, to help predict and prioritise individuals at high risk of developing colon cancer in order to help healthcare teams deliver targeted and proactive interventions.

Professor Finbarr Cotter, Lead for Molecular Pathology and Consultant Haemato-Oncologist at Barts Health, said: “The COVID-19 pandemic has created a challenging situation in which many patients are still awaiting routine treatments and screenings, including for colon cancer, which is the fourth most common cancer in the UK.”

“Integrating EarlySign’s platform into our workstream has helped us to successfully identify patients who would most benefit from screening and intervention, supporting our goal of delivering timely and personalised care to our patients. We are now exploring opportunities to extend our use of EarlySign’s technology to other health areas.”

Itai Katzir, Chief Commercial Officer EU and COO “EarlySign’s Back-to-Care initiative is designed to handle the backlog of postponed treatments due to the coronavirus pandemic, and we are excited to support Barts Health in providing personal and timely treatment for people at high risk of developing serious conditions.”

 “Barts Health is one of the world’s leading health systems and we are proud to count them among our growing international customer base, joining organisations across the US and Europe.”

 

Click here to read the original article

Share:

Share on twitter
Share on linkedin
Share on facebook
Share on email

Are you looking to solve high-burden disease challenges?